Posted by Michael Wonder on 18 Jul 2023
Madrigal Pharmaceuticals completes submission of new drug application seeking accelerated approval of resmetirom for the treatment of NASH with liver fibrosis
17 July 2023 - Madrigal Pharmaceuticals announced the completion of the rolling submission of its new drug application to the US FDA for resmetirom for the treatment of adults with NASH with liver fibrosis, a disease with no approved therapy.
Madrigal has requested a priority review of the resmetirom new drug application.
